𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of anemia in low risk myelodysplastic syndromes with granulocyte–macrophage colony-stimulating factor plus recombinant human erythropoietin

✍ Scribed by Economopoulos, T; Mellou, S; Papageorgiou, E; Pappa, V; Kokkinou, V; Stathopoulou, E; Pappa, M; Raptis, S

Book ID
110054231
Publisher
Nature Publishing Group
Year
1999
Tongue
English
Weight
65 KB
Volume
13
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of severe aplastic anemia with
Treatment of severe aplastic anemia with an immunosuppressive agent plus recombinant human granulocyte-macrophage colony-stimulating factor and erythropoietin
✍ Zonghong Shao; Yulin Chu; Yizhi Zhang; Guibin Chen; Yizhou Zheng 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 2 views

To evaluate the therapeutic potential of hematopoietic growth factors (HGFs) during immunosuppressive treatment (IST) of severe aplastic anemia (SAA), 38 patients with newly diagnosed SAA received IST alone (group I), or IST plus recombinant human erythropoietin and granulocyte-macrophage colony-sti

Combination Therapy With Recombinant Hum
Combination Therapy With Recombinant Human Granulocyte Colony-Stimulating Factor and Erythropoietin in Aplastic Anemia
✍ Dr. Masahiro Imamura; Masanobu Kobayashi; Sumiko Kobayashi; Kohki Yoshida; Chika 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 430 KB 👁 1 views

## Abstract Recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) and erythropoietin (rhEPO) were used to treat patients with aplastic anemia (AA). In terms of effects on erythrocyte recovery, the combined use of rhG‐CSF and rhEPO showed a favorable response in 6 of 14 (42.9%) patients